#Immunotherapy

27 Oct 2026

Personalized vaccine cuts melanoma recurrence after surgery

Adding a personalized mRNA cancer vaccine to pembrolizumab lowered the risk of melanoma returning or dying by 42 %, a phase‑3 trial found.

Read more